Peptide profile
Published Data as of
In a trial in children with hypothalamic growth hormone (GH) deficiency, mean height velocity was 14.6 cm/year on GH and 9.2 cm/year on low-dose sermorelin.1 In the same trial, 20 of 20 children on high-dose sermorelin developed growth hormone-releasing hormone (GHRH) antibodies. So did 19 of 20 on the low dose.1 PepBank's regulatory record shows US approval was withdrawn in 2009 because the maker stopped selling it. Safety and effectiveness were not the reason.2
The FDA approved Geref in 1990 for testing whether the pituitary gland can secrete growth hormone.4 The FDA approved Geref in 1997 for idiopathic growth hormone deficiency in children with growth failure.5
PepBank's regulatory record shows US approval of Geref was withdrawn in 2009 because the maker stopped selling it. That record says the FDA found the withdrawal was not for safety or effectiveness reasons.2
A trial in 43 prepubertal children had hypothalamic growth hormone (GH) deficiency. In this trial, height velocity rose by 2 cm/year or more in all but two children.6 In a trial in children with hypothalamic GH deficiency, growth on either sermorelin dose was significantly worse than on GH.1
In a trial in patients, mean height velocity was 9.2 cm/year on low-dose sermorelin and 9.3 cm/year on the high dose. On GH it was 14.6 cm/year.1 Growth did not differ significantly between the two sermorelin doses in that trial in patients.1
The low dose was 30 micrograms/kg/day, given subcutaneously. It was a studied dose in people in a randomized controlled trial.6 In that trial in patients, height velocity was lowest in the low-dose group.6 Height SDS for bone age rose only in patients on GH. It did not rise on sermorelin.6
In a trial in patients, all 20 children on high-dose sermorelin developed growth hormone-releasing hormone (GHRH) antibodies. On the low dose, 19 of 20 children did.1
In a trial in healthy elderly men and women, a GHRH analog raised GH secretion by 107% and 70% within 4 weeks. The trial integrated the secretion over 12 h.7 Serum IGF-I rose by 28% by 4 weeks in that trial in people and stayed high through 12 weeks.7
In a trial in age-advanced men and women, a GHRH analog raised serum IGF-I within 2 weeks. It stayed elevated for 12 weeks.8 Serum IGFBP-3 also rose within 2 weeks in that trial in people, but IGFBP-1 did not.8
In a trial in adult survivors of childhood brain tumours, continuous GHRH amplified GH release in most people compared with spontaneous release.9 That trial in people used a studied subcutaneous dose of 60 ng/kg/minutes in a randomized controlled trial.9
As of November 15, 2026, PepBank holds 60 studies that gave sermorelin and reported results, with 304 results in total.3 In the sermorelin studies, PepBank holds 43 publications with findings in people. It also holds 10 with findings in animals and 7 with laboratory findings in cells or tissue.3 The trial registry records in PepBank hold 0 registered trials that test sermorelin.3
Sermorelin is one of the peptides in PepBank, with 248 findings in people and 36 findings in animals.3 The sermorelin record behind sermorelin vs tesamorelin holds 20 laboratory findings in cells or tissue and 0 findings predicted by a computer model.3
The table lists studied amounts from trials in people. Each comes from a randomized controlled trial.6,7,8,9,10
| Kind | Dose | Species | Route | Design | Source |
|---|---|---|---|---|---|
| Studied dose | 30 micrograms/kg/day | people | subcutaneous | randomized controlled trial | [6] |
| Studied dose | 10 micrograms/kg | people | subcutaneous | randomized controlled trial | [7] |
| Studied dose | 10 microg/kg | people | subcutaneous | randomized controlled trial | [8] |
| Studied dose | 60 ng/kg/minutes | people | subcutaneous | randomized controlled trial | [9] |
| Studied dose | 10 micrograms | people | intravenous | randomized controlled trial | [10] |
In a trial in age-advanced men and women, a nightly GHRH analog released growth hormone within 10 min, and the release lasted 2 h. The effect continued during the study.8 In a randomized controlled trial in people, 10 adult male volunteers received a studied intravenous dose of 10 micrograms of GHRH(1-29)NH2. Their peak GH was significantly higher than with saline, at 24.03 mU/l.10
In a trial in healthy elderly men and women, a GHRH analog raised B cell responsiveness to mitogens by 50%. T cell responsiveness to phytohemagglutinin rose by 50% by 16 weeks. Lymphocytes with the IL-2 receptor (CD25) rose by 70% at 16 weeks.7 The trial in people found no sex differences in the immune response, and T cell (CD3) numbers did not change.7
In a trial in healthy elderly men and women, the researchers reported no adverse effects with a GHRH analog.7 In a second trial in age-advanced men and women, the analog did not affect blood pressure or body weight.8 In that trial in people, skin thickness rose significantly in both genders, with no other changes in body composition.8
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated